Drugs against ageing

Side by side

The rated projects, compared

Project▲	Promised effect▲	Evidence▲	Stage▲	Strongest case against▲
Aptah Bio	+2 years of life	The strongest evidence is a peer-reviewed Scientific Reports article with iPSC-derived AD neurons and SAMP8 mice, reporting molecular and electrophysiology changes but explicitly no cognitive change in mice.	Preclinical.	The failure case is that Aptah’s claimed breadth is mostly narrative, while the real effects are narrow, model-specific, or too small to translate.
Beijing Joekai Biotechnology	+0.7 years of life	The evidence base is stronger than a pure concept because it includes Joekai-assigned Alzheimer’s patents, a 2025 conference/news report of discovery and preclinical results for 50561, and a completed Phase IIa randomized placebo-controlled trial listing with 68 participants across 12 Chinese sites.	Historically, Joekai held Alzheimer’s-treatment patent filings and grants tied to synthetic compounds, though several records show ceased or fee-related expiry risks.	The evidence base is still dominated by patents, directory entries, and conference/trial metadata without published outcomes, so the project could easily be a case where a plausible mechanism and real clinical activity never translate into meaningful efficacy, differentiation, or durable IP advantage.
NYC-Vita	+1.5 years of life	The project has credible institutional and competition validation: Mount Sinai/NYC-Vita was named an XPRIZE Healthspan semifinalist and Milestone 1 awardee with funding for a New York City clinical trial.	Status is early and unproven.	NYC-Vita could fail because the intervention is a heterogeneous bundle with weak attribution, small sample size, and substantial forward-looking promotional framing; the most likely disappointing outcome is that exercise explains most of the effect, while rapamycin/lamivudine add safety risk, noise, or negligible incremental benefit without clear mechanistic readouts.
RIGHT Trial	+1.2 years of life	The evidence base is thin for the actual frailty indication.	Clinical-stage and actively structured as a mid-stage efficacy/safety test, with University of Pittsburgh as lead sponsor, Anne B.	Frailty is biologically heterogeneous and may not respond meaningfully to single-cytokine suppression; even if IL-6 is associated with frailty, blocking it may produce limited functional benefit, unacceptable tradeoffs, or effects too small to justify chronic biologic treatment in older adults.
Team GlyNAC	+2 years of life	There is more than pure preclinical speculation: evidence includes a randomized older-adult clinical trial, a pilot older-adult clinical trial, mouse lifespan and cognition studies, and smaller disease-context studies in type 2 diabetes and HIV.	Status is early clinical and preclinical, not validated.	The main failure case is that the project is over-extrapolating from small studies, institutional news coverage, and mouse data: biomarker improvements may not translate into durable clinical benefit, lifespan effects may be species-specific, sex-dependent responses may complicate generalization, and Baylor’s patent/licensing position creates conflict-of-interest pressure around interpretation.
Team Twilight	+1.2 years of life	The evidence base supports the broader HERV-K/HML-2 ALS hypothesis better than it supports Team Twilight’s therapeutic program.	The project appears to be a venture-stage therapeutic company in a preclinical or at least not yet clinically validated state based on the evidence here.	The main failure case is that the project is still resting on promotional claims plus field-context biology that does not yet prove intervention efficacy.

Companies

Companies in this direction

Ambition is what a company claims. Independent replication is what others have confirmed. Read the two columns together: the gap between them is where a promise runs ahead of a result.

Company▲	Ambition▲	Independent replication▲	Stage▲	Headquarters▲
5 Alarm Bio 5 Alarm Bio develops small-molecule therapeutics targeting an unexplored aging mechanism to delay or prevent age-related diseases.	7	1	seed	Cambridge, United Kingdom
712 North Inc 712 North develops personalized mitochondrial medicines for age-related diseases.	7	3	–	San Francisco, California, United States
ADvantage Therapeutics ADvantage Therapeutics develops novel therapeutics for neurodegenerative conditions, with a major focus on Alzheimer’s disease.	8	3	–	Vienna, Austria
Aeovian Pharmaceuticals Clinical-stage biopharmaceutical company developing selective small molecules for rare genetic and age-related diseases.	6	1	–	2930 Domingo Avenue #145, Berkeley, CA 94705
AKL Therapeutics AKL Therapeutics develops APPA, an investigational oral therapy for osteoarthritis and other inflammatory diseases of ageing.	6	4	–	Stevenage, United Kingdom
Amplifier Therapeutics Amplifier Therapeutics develops AMPK activators to address metabolic disease and aging-related chronic diseases.	6	2	–	United States
Antoxis Antoxis conducted research and experimental development in biotechnology.	4	2	pre seed	Aberdeen, Scotland, United Kingdom
Atropos Therapeutics Atropos develops senescence-targeting drugs for aging-related diseases, cancer, and healthspan.	7	3	–	San Francisco, California, United States
Biophytis Biophytis develops transformative therapies impacting longevity, with BIO101 programs in sarcopenia and obesity.	7	3	public	Paris, France
Biosplice (was Samumed) Biosplice develops first-in-class therapies based on alternative splicing and small-molecule CLK/DYRK kinase inhibition.	7	2	–	San Diego, California, United States
Bolden Therapeutics Bolden Therapeutics develops first-in-class therapeutics to increase neurogenesis and improve outcomes in neurological disease.	7	1	pre seed	Boston, Massachusetts, United States
Cambrian Bio Clinical-stage drug development company developing therapeutics targeting metabolic pathways that decline with age.	8	2	series c plus	New York, New York
Cognition Therapeutics Cognition Therapeutics develops therapies for age-related neurodegenerative diseases including dementia with Lewy bodies and Alzheimer’s disease.	7	3	public	New York City, New York, United States; Pittsburgh, Pennsylvania, United States
Coya Therapeutics Clinical-stage biotechnology company developing multi-modality Treg therapies for neurodegenerative, autoimmune, and metabolic diseases.	8	4	public	Houston, Texas, United States
Cytonics Cytonics develops A2M-based biologic treatments intended to halt or reverse osteoarthritis progression.	5	2	–	Jupiter, Florida, United States
Epirium Bio Epirium Bio develops oral small-molecule therapies targeting PGE-2 signaling for neuromuscular, inflammatory, and fibrotic diseases.	7	4	series a	United States
Etheros Pharmaceuticals Etheros develops small molecule enzyme mimetics for neuroprotection and healthspan.	7	1	–	United States
Fission Pharma Fission Pharma is developing DRP1-FIS1 protein-protein interaction inhibitors for chronic inflammation, mitochondrial dysfunction, and age-related degenerative diseases.	7	1	pre seed	United States
Fountain Therapeutics Fountain develops first-in-class therapies for diseases and conditions caused by aging.	7	1	–	San Francisco, California, United States
Galilei Biosciences Galilei Biosciences develops small-molecule SIRT6 activators for neuroprotection in glaucoma and other age-related diseases.	7	5	–	Cambridge, Massachusetts, United States
Hayflick Partners Hayflick Therapeutics develops localized, micro-dose rapamycin therapies targeting mTOR for cellular aging interventions in skin.	6	3	–	Narberth, Pennsylvania, United States
HCW Biologics Clinical-stage biopharmaceutical company developing fusion immunotherapies for autoimmune diseases, cancer and senescence-associated dysplasia.	8	3	public	Miami, Florida, United States
Immunis Clinical-stage biotech developing stem cell-derived secretome biologics targeting age-related muscle and metabolic disease.	8	3	–	Irvine, California
Istesso Istesso develops first-in-class oral regenerative medicines focused on restoring the body’s natural capacity to repair tissue.	8	2	–	London, United Kingdom
Jocasta Neuroscience Jocasta develops Klotho-based therapeutics for cognitive vitality and age-related cognitive impairment.	8	4	series a	–
Jupiter Neurosciences A clinical-stage drug platform company focused on treating neuroinflammation.	6	2	–	Palm Beach Gardens, Florida, United States
Juvenescence Juvenescence develops innovative medicines targeting core aging mechanisms to extend healthy lifespan and prevent age-related diseases.	7	2	–	–
LinkGevity LinkGevity develops AI-driven longevity therapeutics, including first-in-class Anti-Necrotic necrosis inhibitors for kidney disease and other applications.	8	2	–	Babraham Research Campus, Cambridge, UK
Loyal Loyal develops longevity drugs for dogs that target age-associated disease and disability.	7	3	series c plus	SAN FRANCISCO
MetroBiotech MetroBiotech develops proprietary NAD+ precursors to enhance human healthspan and treat age-related diseases.	6	3	–	–
Mirscience Therapeutics Mirscience Therapeutics develops personalized microRNA therapies for longevity-associated diseases and challenging therapeutic targets.	7	1	–	Brazil
Mitochem Therapeutics MitoChem Therapeutics develops small molecules targeting mitochondrial dysfunction-driven loss of cellular metabolism in neurodegenerative disease.	7	2	–	Charleston, South Carolina, United States
Mitoconix Bio Mitoconix Bio develops disease-modifying therapeutics for neurodegenerative diseases by improving mitochondrial health.	8	1	–	Israel
Mitotech Mitotech develops orally bioavailable small molecules to protect mitochondria from oxidative stress and enhance energy expenditure.	6	4	–	Russia, Luxembourg
Mogling Bio Mogling Bio develops pharmacological therapies targeting Cdc42 overactivation to rejuvenate aged and exhausted cells, especially stem cells.	8	3	seed	2900 Reading Road Suite #410 Cincinnati OH 45206
Muna Therapeutics Muna Therapeutics develops therapies to slow or stop neurodegenerative diseases including Alzheimer’s and Parkinson’s.	8	3	–	Copenhagen, Denmark
Napa Therapeutics Napa Therapeutics develops small molecule drugs against a novel aging-related target linked to NAD metabolism.	7	1	–	San Francisco, California, United States
NeuroBio Neuro-Bio develops diagnostic and therapeutic strategies for Alzheimer's disease based on the toxic T14 peptide mechanism.	8	2	seed	Oxford, United Kingdom
NRG Therapeutics NRG Therapeutics develops disease-modifying medicines for neurodegenerative disorders by targeting mitochondrial function.	8	2	–	Stevenage, Hertfordshire United Kingdom
NuSirt NuSirt Sciences combines established pharmaceuticals and natural products to activate the sirtuin pathway for cardiometabolic diseases of aging and overnutrition.	5	3	–	Knoxville, Tennessee, United States
Olatec Olatec develops safe oral NLRP3 antagonist therapeutics for acute and chronic inflammatory diseases.	7	5	–	New York City, New York, United States; Boston, Massachusetts, United States
Pelage Pharmaceuticals Pelage develops regenerative medicines for hair loss grounded in stem cell biology.	6	3	series b	Los Angeles, California, United States
PharmatrophiX PharmatrophiX develops small-molecule disease-modifying therapies for neurodegenerative diseases.	8	4	–	San Francisco, California, United States
Praetego	7	2	–	Durham, North Carolina, United States
Pretzel Therapeutics Pretzel develops first-in-class medicines targeting mitochondrial biology and cellular energetics for rare, neurodegenerative, metabolic, and other diseases.	8	4	series a	Sweden; Boston, Massachusetts, United States
Refoxy Pharma Refoxy develops next-generation medicines targeting FOXO3 to treat age-related diseases and extend healthy lifespan.	7	2	–	Germany
ReGENE ReGENE develops small molecule therapies to prevent and treat aging-associated diseases by targeting mechanisms that drive aging.	7	1	–	Springfield, Massachusetts, United States
resTORbio Clinical-stage biopharmaceutical company developing medicines targeting the biology of aging to prevent or treat aging-related diseases.	7	2	–	Boston, Massachusetts, United States
Retrotope Retrotope develops proprietary therapeutics designed to treat degenerative disease by down-regulating lipid peroxidation.	7	4	series c plus	San Francisco, California, United States
Scripta Therapeutics Scripta Therapeutics modulates transcription factor activity using AI/ML-driven drug discovery to develop disease-modifying therapeutics.	8	0	–	Oxford, United Kingdom
Senisca Senisca develops RNA senotherapeutics to reverse cellular senescence and treat age-related disease.	8	1	seed	Exeter, United Kingdom
Sentcell Sentcell develops first-in-class human rejuvenating therapies targeting the sMAC pathway in ageing T cells.	9	2	series a	London, United Kingdom
Ship of Theseus A therapeutics company developing degradation-resistant Hox family biologics.	7	4	–	Philadelphia, Pennsylvania, United States
Sierra Sciences Sierra Sciences researches telomere science and telomerase activation to develop interventions intended to reverse cellular aging.	8	0	–	Reno, Nevada, United States
TNF Pharmaceuticals (was MyMD) Clinical-stage biopharma developing MYMD-1 and Supera-CBD for autoimmune, inflammatory, aging-related, pain, anxiety and seizure indications.	6	2	public	Baltimore, Maryland, United States
TOR Therapeutics TOR Therapeutics develops an oral fixed-dose combination of mTORC1 inhibitors for Alzheimer's disease and other mTORC1-driven disorders.	7	0	–	Jenkintown, Pennsylvania, United States
Tornado Therapeutics Tornado Therapeutics is developing safer, more effective rapalogs to treat disease and extend healthy lifespan.	8	0	–	United States
Trivium Vet TriviumVet develops animal health therapeutics for serious diseases in cats and dogs.	6	4	acquired	Ireland
Vasa Therapeutics Vasa develops therapeutics targeting cardiovascular aging, neuromuscular disease, and age-related disorders.	7	2	seed	Encinitas, California, United States
X-tosis X-tosis develops mitochondrial therapeutics to prevent neuronal loss in neurodegenerative diseases.	8	2	–	Gainesville, Florida, United States
YOXLO YOXLO builds science-based tools, products and research programs to help people understand and preserve functional reserve as they age.	7	2	pre seed	YOXLO B.V. Biopartner 5 Building De Limes 7 2343 DH Oegstgeest
Zoe Biosciences Zoe Biosciences is developing best-in-class therapies to treat cardiometabolic disease.	6	0	–	United States

Projects

Projects in this direction

Project▲	Stage▲	Strongest case against▲
A NEW DIMENSION A NEW DIMENSION appears to be Aayam Therapeutics’ mitochondria-focused longevity effort: a drug-discovery and development project built around an undisclosed "LADR 4" platform and framed as delivering affordable, accessible therapeutics.	Early but real.	The project may fail because its public evidence is currently far weaker than its positioning: the mechanism is opaque, the platform is undefined, and mitochondria is a crowded, hype-prone area where patenting, competition recognition, and expert biography do not by themselves predict clinical efficacy.
Alpha Rejuvenation Alpha Rejuvenation appears to be a California-focused men’s health and wellness clinic marketing peptide therapies, testosterone replacement, erectile-dysfunction treatment, pelvic-floor therapy, NAD+, and semaglutide-based weight loss rather than a clearly documented R&D program.	Operational as a men’s rejuvenation clinic with named services, office details, and a stated licensing footprint limited to California and Arizona.	This may be mostly a marketing-driven men’s wellness clinic aggregating loosely supported interventions, with weak causal evidence, heavy reliance on testimonials and educational copy, unclear differentiation from standard cash-pay hormone/weight-loss practice, and a material evidence-quality problem around source attribution.
Aptah Bio Aptah Bio is a U.S.-based startup developing RNA therapeutics, centered on a U1 snRNP-modulating platform it calls RNA WiCo/RNA rejuvenation, for neurodegeneration, cancer, and other age-related diseases.	Preclinical.	The failure case is that Aptah’s claimed breadth is mostly narrative, while the real effects are narrow, model-specific, or too small to translate.
Beijing Joekai Biotechnology Beijing Joekai Biotechnology appears to be a Beijing-based small-molecule neurodegeneration company centered on Alzheimer’s disease.	Historically, Joekai held Alzheimer’s-treatment patent filings and grants tied to synthetic compounds, though several records show ceased or fee-related expiry risks.	The evidence base is still dominated by patents, directory entries, and conference/trial metadata without published outcomes, so the project could easily be a case where a plausible mechanism and real clinical activity never translate into meaningful efficacy, differentiation, or durable IP advantage.
Beiwe Beiwe appears to be an early therapeutic project centered on selective mTORC1 inhibition for longevity and cancer, with the core claim that it can preserve rapamycin-like benefits while avoiding mTORC2-related toxicity; however, the evidence here is mostly undated self-published website copy with no linked primary datasets, study details, patent record tied to the company, or disclosed clinical results.	Publicly presented as a company with a therapeutic thesis and named team members including Gino Cortopassi, PhD, and Zane Starkewolfe, PhD, but the supplied evidence does not show Beiwe-specific preclinical datasets, peer-reviewed papers, patents assigned to the project, trial registrations, or clinical-stage progress.	The current evidence does not substantiate the key claims.
BioArmor BioArmor appears to be an early-stage, student-led longevity concept from the QuestX Incubator in Kuala Lumpur that reached XPRIZE Healthspan semifinalist status, but the public evidence does not disclose a validated therapeutic program.	Status is best described as concept-stage with publicity and competition recognition but little disclosed validation.	The downside case is stronger on current evidence: BioArmor may be mostly a narrative bundle of popular longevity ingredients plus futuristic claims that are far ahead of any disclosed proof.
Cura Therapeutics and collaborators/ Cura Therapeutics appears to be a small, women-led biotech developing multifunctional fusion-protein therapeutics for metastatic cancer and age-related diseases, with recurring claims around multimodal immune activation plus anti-fibrotic and anti-senescence effects.	Status is best described as early translational with inconsistent but convergent signals of advancement.	The project may fail because most of the current support is still promotional, patent-based, or inherited from older academic fusokine work rather than direct proof that Cura's own candidates are effective, manufacturable, and safe in humans.
Klotho Longevity Klotho Longevity is a U.S. commercialization effort centered on Klotho-linked anti-aging products and procedures, led by Dr.	Current status appears to be an operating U.S. clinic-and-brand ecosystem with active commercialization, promotional conference visibility, and at least one granted Klotho-production patent linked to Gail Humble.	The downside case is that this is mostly a branding-and-patent story built on a biologically interesting target without adequate proof that project-specific products deliver meaningful human longevity benefits.
Lono Jaeyak Lono Jaeyak appears to be an anti-senescence composition program known only from a pending European patent application claiming formulations for rejuvenating senescent cells or delaying/preventing cellular aging.	Status is early and weakly validated.	The downside case is that this is only a broad patent filing with little evidentiary substance behind it.
Nishimura Lab Nishimura Lab appears, on the evidence provided, to be an EADERM-linked regenerative dermatology effort built around hair follicle and epidermal stem-cell biology, especially aging- and injury-related mechanisms involving COL17A1 and stem-cell motility.	Preclinical and early commercial.	This project could fail because the current evidence is still mostly a chain of academic titles, patents, and company positioning rather than hard translational proof.
NYC-Vita NYC-Vita is a Mount Sinai-led, New York City pilot longevity trial that appears to combine home-based exercise, daily spermidine, and low-dose rapamycin or lamivudine in adults roughly 65-80, with the stated goal of improving immune function, muscle strength, cognition, and overall healthspan.	Status is early and unproven.	NYC-Vita could fail because the intervention is a heterogeneous bundle with weak attribution, small sample size, and substantial forward-looking promotional framing; the most likely disappointing outcome is that exercise explains most of the effect, while rapamycin/lamivudine add safety risk, noise, or negligible incremental benefit without clear mechanistic readouts.
RIGHT Trial RIGHT Trial appears to be a University of Pittsburgh-led Phase 2, 24-week, placebo-controlled trial testing subcutaneous clazakizumab, an IL-6 blocker, in older adults with frailty and mobility limitation.	Clinical-stage and actively structured as a mid-stage efficacy/safety test, with University of Pittsburgh as lead sponsor, Anne B.	Frailty is biologically heterogeneous and may not respond meaningfully to single-cytokine suppression; even if IL-6 is associated with frailty, blocking it may produce limited functional benefit, unacceptable tradeoffs, or effects too small to justify chronic biologic treatment in older adults.
Team GlyNAC Team GlyNAC appears to be a Baylor College of Medicine-associated translational longevity project built around GlyNAC, a glycine plus N-acetylcysteine supplementation strategy intended to raise glutathione and improve mitochondrial and oxidative-stress-related aging defects.	Status is early clinical and preclinical, not validated.	The main failure case is that the project is over-extrapolating from small studies, institutional news coverage, and mouse data: biomarker improvements may not translate into durable clinical benefit, lifespan effects may be species-specific, sex-dependent responses may complicate generalization, and Baylor’s patent/licensing position creates conflict-of-interest pressure around interpretation.
Team Twilight Team Twilight is a U.S. biotech startup developing active immunotherapies against pathological proteins, especially HERV-K-linked targets in ALS, with broader stated ambitions in Alzheimer’s, Parkinson’s, and chronic pain.	The project appears to be a venture-stage therapeutic company in a preclinical or at least not yet clinically validated state based on the evidence here.	The main failure case is that the project is still resting on promotional claims plus field-context biology that does not yet prove intervention efficacy.
The Brigham Boston XPrize The Brigham-Boston XPRIZE Healthspan Team is a Mass General Brigham and Harvard-linked effort that became a Top 40 semifinalist in the seven-year, $101M XPRIZE Healthspan competition and received $250,000 in Milestone 1 funding in 2025.	As of May 12, 2025, the team was named a Top 40 semifinalist in XPRIZE Healthspan and awarded $250,000 in Milestone 1 funding.	The main failure mode is that the project remains high-profile but underspecified: the therapeutic is unnamed, the evidence is currently promotional rather than experimental, and the pilot may fail to produce endpoints or biomarkers that are persuasive enough to support a larger trial or any real conclusion about healthspan benefit.
TIME TRAVELER AND NUREKI TIME TRAVELER AND NUREKI presents as a University of Tokyo-linked startup pursuing healthy-aging products and therapeutics, especially plant-cell-derived exosomes and molecules said to inhibit aging-linked genes, with stated interests in cancer, frailty/sarcopenia, cachexia, supplements, and cosmetics.	Early-stage startup.	The main failure case is that the project is currently much stronger in narrative, patent-adjacent field context, and product marketing than in demonstrated science.
YOXLO YOXLO is a Dutch longevity startup building a proprietary healthspan intervention, Youniqor, around a centenarian-inspired thesis that mitochondrial function, cellular resilience, and inflammatory control, especially NLRP3-linked immune signaling, can be modulated to preserve strength, cognition, independence, and immune function with age.	YOXLO has a named founder and cofounding team, a live company website in 2025, SAFE fundraising, and XPRIZE Healthspan semifinalist recognition.	The strongest failure case is that YOXLO is currently much stronger on narrative, patents, and competition signaling than on disclosed evidence, and that its broad claims about mitochondria, oxidative stress, immune balance, and NLRP3 will not survive rigorous testing because the formulation effect size is small, nonspecific, or not mechanistically tied to the promised healthspan outcomes.

People

People in this direction

Aubrey de Greypopulariser · through Sierra Sciences
SENS Foundation founder and longevity advocacy pioneer.
Alex Zhavoronkovpopulariser · through Napa Therapeutics
João Pedro de Magalhãesscientist · through 5 Alarm Bio
Senescence.info founder and aging-database builder.
Matt Kaeberleinscientist · through Hayflick Partners
Laura Deminginvestor · through Loyal
Founded The Longevity Fund as an early dedicated VC vehicle for aging and life-extension companies, helping make longevity biotech a fundable startup category.
Eric Verdinscientist · through BHB Therapeutics
Celine Haliouaentrepreneur · through Loyal
Biotech founder pursuing the first approved lifespan-extension drugs for dogs
Nir Barzilaiscientist · through SirtLab Corp
Daisy Robintonentrepreneur · through Tornado Therapeutics
Biotech founder developing therapeutics for ovarian aging and women’s health
Kristen Fortneyentrepreneur · through BioAge Labs
Jim Mellonentrepreneur · through Napa Therapeutics
Co-founded Juvenescence and publicly framed longevity as an investable biotechnology thesis through the book Juvenescence and substantial company-building activity.
James Peyerentrepreneur · through Amplifier Therapeutics
Biotech builder translating aging biology into a portfolio of medicines
David Sinclairscientist · through MetroBiotech
Joe Betts-LaCroixentrepreneur · through BioAge Labs
Biotech entrepreneur building therapies for age-driven disease
Christian Angermayerentrepreneur · through Cambrian Bio
Kelsey Moodyentrepreneur · through Ship of Theseus
Drug-development entrepreneur building an integrated longevity biotech platform
Peter Diamandisentrepreneur · through Immunis

Chronology

What happened, and when

Hypotheses

Hypotheses under test in this direction

Published by the Omega Point engine and tagged to this direction by a classifier; the gap each one attacks is named under it

All hypotheses →

Forecasts

What the forecasts expect here

All forecasts →

This month

Reported recently

All news →